Dusan Perovic

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

Freeform builds AI-native manufacturing systems that unify software, hardware, and physics to produce industrial-scale parts at the speed of human ideation. By treating manufacturing as a single integrated system, we unlock a new era of innovation where complex hardware is designed, built, and scaled without limits. We are a team of first-principles thinkers driven by a shared mission: to build the fundamental technology that moves the world forward. We believe that solving the foundational challenges of production requires a massive diversity of expertise, deep collaboration, low ego, and a healthy sense of humor. Whether you are an engineer, a builder of systems, or a creative problem-solver in any field, we invite you to help us align the physical world with the pace of human imagination. We are backed by industry leading VCs including Founders Fund, NVIDIAs NVenures, Threshold Ventures, Two Sigma Ventures, Linse Capital, 8VC, Valor, and more who share our conviction in scaling Physical AI to revolutionize manufacturing.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it’s always possible.

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Isabl integrates the whole genome and transcriptome to inform cancer care

Hexagon Bio is a data-driven biopharma company developing targeted small molecule therapeutics. Our proprietary platform combines data science, genomics, synthetic biology, chemistry and automation to discover potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.

Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company’s platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning and AI algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Deviation Capital is an early-stage venture firm investing at Seed and Series A in technical founders harnessing the accelerating forces of data and computing. Our portfolio spans consumer, enterprise, and life sciences, including WHOOP, Remote, Xaira, Kalshi, Gameto, Etched, and others building at the intersection of data, software, and advanced computing. Were based in New York and San Francisco. Deviation was launched in 2026 following the spinout of the Two Sigma Ventures business from quantitative investment and trading firm Two Sigma.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

Freeform builds AI-native manufacturing systems that unify software, hardware, and physics to produce industrial-scale parts at the speed of human ideation. By treating manufacturing as a single integrated system, we unlock a new era of innovation where complex hardware is designed, built, and scaled without limits. We are a team of first-principles thinkers driven by a shared mission: to build the fundamental technology that moves the world forward. We believe that solving the foundational challenges of production requires a massive diversity of expertise, deep collaboration, low ego, and a healthy sense of humor. Whether you are an engineer, a builder of systems, or a creative problem-solver in any field, we invite you to help us align the physical world with the pace of human imagination. We are backed by industry leading VCs including Founders Fund, NVIDIAs NVenures, Threshold Ventures, Two Sigma Ventures, Linse Capital, 8VC, Valor, and more who share our conviction in scaling Physical AI to revolutionize manufacturing.